Cubist Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST PHARMS, and when can generic versions of CUBIST PHARMS drugs launch?
CUBIST PHARMS has seven approved drugs.
There are thirty US patents protecting CUBIST PHARMS drugs.
There are three hundred and forty-one patent family members on CUBIST PHARMS drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Drugs and US Patents for Cubist Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cubist Pharms Llc | DIFICID | fidaxomicin | FOR SUSPENSION;ORAL | 213138-001 | Jan 24, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 8,476,425 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Cubist Pharms Llc | ZERBAXA | ceftolozane sulfate; tazobactam sodium | POWDER;INTRAVENOUS | 206829-001 | Dec 19, 2014 | RX | Yes | Yes | 9,724,353 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cubist Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 6,469,030 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,468,967 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
International Patents for Cubist Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 6101010 | ⤷ Try a Trial |
Argentina | 123846 | ⤷ Try a Trial |
China | 102516238 | ⤷ Try a Trial |
South Africa | 201505048 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cubist Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1699784 | C300759 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLID, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/15/991 20150323 |
1539977 | 1590020-2 | Sweden | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN; TOTAL VALIDITY PERIOD: 16 JULY 2023 THROUGH 6 JUNE 2027 |
1699784 | C20150036 00229 | Estonia | ⤷ Try a Trial | PRODUCT NAME: TEDISOLIIDFOSFAAT;REG NO/DATE: EU/1/15/991 25.03.2015 |
1699784 | 132016000024232 | Italy | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLID, FACOLTATIVAMENTE IN FORMA DI ESTERE, IN PARTICOLARE UN FOSFATO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(SIVEXTRO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/991/001, 20150325 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.